Recent research highlights the pivotal role of gut microbiota and bile acids as modulators of metabolic homeostasis in type 2 diabetes (T2D). The concomitant use of probiotics and ursodeoxycholic acid (UDCA) may potentiate glycemic and lipid control via complementary mechanisms.
Objective
To evaluate the metabolic effects of probiotic supplementation and its combination with UDCA in metformin-treated T2D patients.
Methods
In this monocentric, prospective, randomized, double-blind, controlled trial, 90 patients with T2D on metformin therapy were randomized into three groups: metformin-only (MG), metformin plus probiotic (MPG), and metformin plus probiotic plus UDCA (MPUG). The intervention lasted 4 weeks. Primary outcomes included changes in fasting glucose, postprandial glucose and HbA1c. Secondary outcomes included lipid profile, C-reactive protein (CRP), and fecal levels of probiotics and UDCA. Two visits were conducted during the study - at the beginning and at the end. Visits involved patient interviews, clinical data collection, anthropometric measurements, blood biochemical analyses, and stool sample analysis for the presence of probiotic culture and UDCA concentrations.
Results
After 4 weeks, the MPUG group showed a significant reduction in fasting glucose (−1.7 mmol/L; 95% CI: −2.2 to −1.2), postprandial glucose (−1.3 mmol/L; 95% CI: −1.8 to −0.7), and HbA1c (−0.49%; 95% CI: −0.66 to −0.31) compared to the MG group. Total cholesterol and LDL cholesterol were also significantly reduced, while HDL increased. The concentration of Lactobacillus rhamnosus GG was highest in the MPUG group. No serious adverse events were reported.
Conclusion
Co-administration of probiotics and UDCA for four weeks in metformin-treated T2D patients significantly improves short-term glycemic control and lipid profiles. These promising results warrant validation in larger, longer-term clinical trials.
SugandhFChandioMRaveenaF, et al.Advances in the management of diabetes Mellitus: a focus on personalized medicine. Cureus2023 Aug 18; 15: e43697.
2.
MouriMIBadireddyM. Hyperglycemia.[Updated 2023 Apr 24]. In: StatPearls[Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan. Available at: https://www.ncbi.nlm.nih.gov/books/NBK430900/.
3.
BoutouyriePClimieREBrunoRM. Type 2 diabetes Mellitus, interaction between left ventricle and large arteries. Am J Hypertens2022 May 10; 35: 388–390.
4.
HossainMJAl-MamunMIslamMR. Diabetes mellitus, the fastest growing global public health concern: early detection should be focused. Health Sci Rep2024 Mar 22; 7: e2004.
5.
CandoLFTQuebralEPBOngEP, et al.Current status of diabetes mellitus care and management in the Philippines. Diabetes Metab Syndr2024 Feb; 18: 102951.
6.
DaoLChoiSFreebyM. Type 2 diabetes mellitus and cognitive function: understanding the connections. Curr Opin Endocrinol Diabetes Obes2023 Feb 1; 30: 7–13.
7.
de Lourdes Ochoa-GonzálezFGonzález-CurielIECervantes-VillagranaAR, et al.Innate immunity alterations in type 2 diabetes Mellitus: understanding infection susceptibility. Curr Mol Med2021; 21: 318–331.
8.
SaeediPPetersohnISalpeaP, et al.IDF Diabetes Atlas Committee. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition.
9.
MemonHAbdullaFReljicT, et al.Effects of combined treatment of probiotics and metformin in management of type 2 diabetes: a systematic review and meta-analysis. Diabetes Res Clin Pract2023 Aug; 202: 110806.
10.
ForetzMGuigasBViolletB. Understanding the glucoregulatory mechanisms of metformin in type 2 diabetes mellitus. Nat Rev Endocrinol2019; 15: 569–589.
11.
LiTProvidenciaRMuN, et al.Association of metformin monotherapy or combined therapy with cardiovascular risks in patients with type 2 diabetes mellitus. Cardiovasc Diabetol2021; 20: 30.
12.
ZangiabadianMNejadghaderiSAZahmatkeshMM, et al.The efficacy and potential mechanisms of metformin in the treatment of COVID-19 in the diabetics: a systematic review. Front Endocrinol (Lausanne)2021 Mar 19; 12: 645194.
13.
LiYYangXYanP, et al.Metformin in patients with COVID-19: a systematic review and meta-analysis. Front Med (Lausanne)2021 Aug 19; 8: 704666.
14.
GaneshARandallMD. Does metformin affect outcomes in COVID-19 patients with new or pre-existing diabetes mellitus? A systematic review and meta-analysis. Br J Clin Pharmacol2022 Jun; 88: 2642–2656.
15.
AlaMAlaM. Metformin for cardiovascular protection, inflammatory bowel disease, osteoporosis, periodontitis, polycystic ovarian syndrome, neurodegeneration, cancer, inflammation and senescence: what is next?ACS Pharmacol Transl Sci2021 Nov 1; 4: 1747–1770.
16.
GurungMLiZYouH, et al.Role of gut microbiota in type 2 diabetes pathophysiology. EBioMedicine2020 Jan; 51: 102590.
17.
ZhouZSunBYuD, et al.Gut microbiota: an important player in type 2 diabetes mellitus. Front Cell Infect Microbiol2022; 12: 834485.
18.
KhoslaSSamakkarnthaiPMonroeDG, et al.Update on the pathogenesis and treatment of skeletal fragility in type 2 diabetes mellitus. Nat Rev Endocrinol2021 Nov; 17: 685–697.
19.
OzsoySSultanogluNSanlidagT. The role of Mediterranean diet and gut microbiota in type- 2 diabetes mellitus associated with obesity (diabesity). J Prev Med Hyg2022 Oct 17; 63: E87–E92.
20.
De VosWMTilgHVan HulM, et al.Gut microbiome and health: mechanistic insights. Gut2022; 71: 1020–1032.
21.
LiXLiuLCaoZ, et al.Gut microbiota as an “invisible organ” that modulates the function of drugs. Biomedicine and Pharmacotherapy2020; 121: 109653. DOI: doi.org/10.1016/j.biopha.2019.109653
22.
CaniPDAmarJIglesiasMA, et al.Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes2007; 56: 1761–1772.
23.
HauserGBenjak HorvatIZelićM, et al.Probiotici i prebiotici – koncept. Medicus2020; 29: 95–114.
24.
PanwarHRashmiHMBatishVK, et al.Probiotics as potential biotherapeutics in the management of type 2 diabetes – prospects and perspectives. Diab Met Res et Rev2013; 29: 103–112
25.
ParkK-YKimBHyunCK. Lactobacillus rhamnosus GG improves glucosae tolerance through alleviating ER stress and suppressing macrophage activation in dg/db mice. J Clin Biochem Nutr2015; 56: 240–246.
26.
ParkSZhangTKangS. Fecal Microbiota composition, their interactions, and metagenome function in US adults with type 2 diabetes according to enterotypes. Int J Mol Sci2023; 24: 9533.
27.
MilajerdiAMousaviSMSadeghiA, et al.The effect of probiotics on inflammatory biomarkers: a meta-analysis of randomized clinical trials. Eur J Nutr2020; 59: 633–649.
28.
MohrAEBasileAJCrawfordMS, et al.Probiotic supplementation has a limited effect on circulating immune and inflammatory markers in healthy adults: a systematic review of randomized controlled trials. J Acad Nutr Diet2020; 120: 548–564.
29.
BuiTNYPaulAGuleriaS, et al.Short-chain fatty acids—a key link between the gut microbiome and T-lymphocytes in neonates?Pediatr Res2025. https://doi.org/10.1038/s41390-025-04075-0
30.
Chavez-TalaveraOTrailleuxALefebvreP, et al.Bile acid control of metabolism and inflammation in obesity, type 2 diabetes, dyslipidaemia, and nonalcoholic fatty liver disease. Gatroeneterology2017; 152: 1679–1694.
31.
LazarevićSĐanićMGoločorbin-KonS, et al.Semisynthetic bile acids: a new therapeutic option for metabolic syndrome. Pharmacol Res2019 Aug; 146: 104333.
32.
HolterMMChirikjianMKBriereDA, et al.Compound 18 improves glucose tolerance in a hepatocyte TGR5-dependent manner in mice. Nutrients2020; 12: 2124.
33.
LinXXiaLZhouY, et al.Crosstalk between bile acids and intestinal epithelium: multidimensional roles of farnesoid X receptor and takeda G protein receptor 5. Int J Mol Sci2025; 26: 4240.
34.
GuanBTongJHaoH, et al.Bile acid coordinates microbiota homeostasis and systemic immunometabolism in cardiometabolic diseases. Acta Pharm Sin B2022; 12: 2129–2149.
35.
GaoRMengXXueY, et al.Bile acids-gut microbiota crosstalk contributes to the improvement of type 2 diabetes mellitus. Front Pharmacol2022; 13: 1027212.
36.
PolandJCFlynnCR. Bile acids, their receptors, and gut microbiota. Physiol (Bethesda)2021; 36: 235–245.
37.
LiYWangLYiQ, et al.Regulation of bile acids and their receptor FXR in metabolic disease. Front Nutr2024; 11: 1447878.
38.
KuklaMKierachRSkoniecznaM, et al.Influence of ursodeoxycholic acid therapy on levels of fibroblast growth factor 21, adiponectin and biochemical parameters in intrahepatic cholestasis of pregnancy. Clin Exp Hepatol2021 Mar; 7: 13–24.
39.
DabkeKHendrickGDevkotaS. The gut microbiome and metabolic syndrome. J Clin Invest2019; 10: 4050–4057.
40.
WuJYangKFanH, et al.Targeting the gut microbiota and its metabolites for type 2 diabetes mellitus. Front Endocrinol (Lausanne)2023; 14: 1114424.
41.
Di VincenzoFDel GaudioAPetitoV, et al.Gut microbiota, intestinal permeability, and systemic inflammation: a narrative review. Intern Emerg Med2024 Mar; 19: 275–293.
42.
LeeD-HKimM-THanJ-H. GPR41 And GPR43: from development to metabolic regulation. Biomed & Pharmacotherapy2024; 175: 116735.
43.
GoodyearMDKrleza-JericKLemmensT. The declaration of Helsinki. Br Med J2007 Sep 29; 335: 624–625.
44.
HopewellSChanAWCollinsGS, et al.CONSORT 2025 Statement: updated guideline for reporting randomised trials. Nat Med2025; 31: 1776–1783.
45.
FaulFErdfelderEBuchnerA, et al.Statistical power analyses using GPower 3.1: tests for correlation and regression analyses. Behav Res Methods2009; 41: 1149–1160.
46.
XunZYaoXLinC, et al.A novel therapy targeting the gut–liver axis for chronic hepatitis B: ursodeoxycholic acid plus Bifidobacterium. JHEP Reports2025; 7: 101456.
47.
LakićBŠkrbićRUletilovićS, et al.Beneficial effects of ursodeoxycholic acid on metabolic parameters and oxidative stress in patients with type 2 diabetes Mellitus: a randomized double-blind, placebo-controlled clinical study. J Diabetes Res2024; 2024: 4187796.
48.
American Diabetes Association. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes – 2021. Diabetes Care2021; 44: S111–S124.
49.
LeeJKimMHJangJY, et al.Assessment HOMA as a predictor for new onset diabetes mellitus and diabetic complications in non-diabetic adults: a KoGES prospective cohort study. Clin Diabetes Endocrinol2023 Nov 16; 9: 7.
50.
ShehataHRHassaneBNewmasterSG. Real-time polymerase chain reaction methods for strain specific identification and enumeration of strain Lacticaseibacillus paracasei 8700:2. Front Microbiol2023; 13: 1076631.
51.
KimEYangSMLimB, et al.Design of PCR assays to specifically detect and identify 37 Lactobacillus species in a single 96 well plate. BMC Microbiol2020; 20. https://doi.org/10.1186/s12866-020-01781-z
52.
JungersenMWindAJohansenE, et al.The science behind the probiotic strain Bifidobacterium animalis subsp. lactis BB-12(®). Microorganisms2014 Mar 28; 2: 92–110.
53.
XiaoYWangCZhaoJ, et al.Quantitative detection of Bifidobacterium longum strains in feces using strain-specific primers. Microorganisms2021 May; 9: 1159.
54.
ZhaoXLiuZSunF, et al.Bile acid detection techniques and bile acid-related diseases. Front Physiol2022 Mar 16; 13: 826740.
55.
HeYShaoyongWChenY, et al.The functions of gut microbiota-mediated bile acid metabolism in intestinal immunity. J Adv Res2025; 80: 351–370. https://doi.org/10.1016/j.jare.2025.05.015
56.
ChenBBaiYTongF, et al.Glycoursodeoxycholic acid regulates bile acids level and alters gut microbiota and glycolipid metabolism to attenuate diabetes. Gut Microbes2023; 15: 2192155. DOI: https://doi.org/10.1080/19490976.2023.2192155
57.
ĐanićMPavlovićNStanimirovB, et al.PAMPA Model of gliclazide permeability: the impact of probiotic bacteria and bile acids. Eur J Pharm Sci2021 Mar 1; 158: 105668.
58.
PavlovićNStankovKMikovM. Probiotics–interactions with bile acids and impact on cholesterol metabolism. Appl Biochem Biotechnol2012 Dec; 168: 1880–1895.
59.
ZhangCZhangQZhangX, et al.Effects of synbiotics surpass probiotics alone in improving type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled trial. Clin Nutr2025; 44: 248–258.
60.
ChenZRadjabzadehDChenL, et al.Association of insulin resistance and type 2 diabetes with gut microbial diversity: a microbiome- wide analysis from population studies. JAMA Netw Open2021; 4: e2118811.
61.
WangCZhangCLiS, et al.Effects of probiotic supplementation on dyslipidemia in type 2 diabetes Mellitus: a meta-analysis of randomized controlled trials. Foods2020; 9: 1540.
62.
DempseyECorrSC. Lactobacillus spp. For gastrointestinal health: current and future perspectives. Front Immunol2022; 13: 840245.
63.
CunninghamALStephensJWHarrisDA. Gut microbiota influence in type 2 diabetes mellitus. Gut Pathog2021; 13: 50. Published online 2021 Aug 6.
64.
SalgaçoMKOliveiraLGSCostaGN, et al.Relationship between gut microbiota, probiotics, and type 2 diabetes mellitus. Appl Microbiol Biotechnol2019; 103: 9229–9238.
65.
SanbornVEAzcarate-PerilMAGunstadJ. Lactobacillus rhamnosus GG and HbA1c in middle age and older adults without type 2 diabetes mellitus: a preliminary randomized study. Diabetes Metab Syndr2020; 14: 907–909.
66.
GuptaSKamatTChawlaR, et al.Probiotic supplementation (vibact DS) in patients with type 2 diabetes Mellitus: real-world experience from India. J Diabetol2022; 13: 101.
67.
MadempudiRSAhireJJNeelamrajuJ, et al.Efficacy of UB0316, a multi-strain probiotic formulation in patients with type 2 diabetes mellitus: a double blind, randomized, placebo controlled study. PLoS One2019; 2019: e0225168.
68.
BudijitnoSArwidyardiALestariES, et al.Probiotic and ursodeoxycholic acid combination improves microbial gut dysbiosis and bilirubin levels in cholestatic rats. J Pharm Pharmacogn Res2025; 13: 1160–1167.
69.
BaiX-PDuW-JXingH-B, et al.Influence of ursodeoxycholic acid on blood glucose, insulin and GLP-1 in rats with liver fibrosis induced by bile duct ligation. Diabetol Metabo Syndr2023; 15: 18.
70.
LiJDawsonPA. Animal models to study bile acid metabolism. BBA – Mol Basis Dis2019; 1865: 895–911.
71.
Sanchez-GarciaASahebkarASimental-MendiaM, et al.Effect of ursodeoxycholic acid on glycemic markers: a systematic review and meta-analysis of clinical trials. Pharmacol Res2018, Sept; 135: 144–149.
72.
ChenYShenXMaT, et al.Adjunctive probio-X treatment enhances the therapeutic effect of a conventional drug in managing type 2 diabetes Mellitus by promoting short-chain fatty acid-producing Bacteria and bile acid pathways. mSystems2023; 8: e0130022.
73.
KocsisTMolnarBNemethD, et al.Probiotics have beneficial metabolic effects in patients with type 2 diabetes mellitus: a meta-analysis of randomized clinical trials. Sci Rep2020; 10: 11787.
74.
CheongEKimJYong-SuJ, et al.Elucidation of the fucose metabolism of probiotic Lactobacillus rhamnosus GG by metabolomic and flux balance analyses. J Biotechnol2022 Dec; 360: 110–116.
75.
HowardEJLamTKDucaFA. The gut microbiome: connecting diet, glucose homeostasis, and disease. Annu Rev Medi2022 Jan 27; 73: 469–481.
76.
ErawijantariPPMizutaniSShiromaH, et al.Influence of gastrectomy for gastric cancer treatment on faecal microbiome and metabolome profiles. Gut2020; 69: 1404–1415.
77.
MilivojacTGrabežMKrivokućaA, et al.Ursodeoxycholic and chenodeoxycholic bile acids attenuate systemic and liver inflammation induced by lipopolysaccharide in rats. Mol Cell Biochem2024; 480: 563–576. DOI: 10.1007/s11010-024-04994-2
78.
SuvajdzicLStojakovicNMikovM, et al.Influence of bile acid on rat gut Microflora deterioration induced by oral ampicillin treatment. Acta Sci Vet2015; 43: 1282.
79.
SunLXieCWangG, et al.Gut microbiota and intestinal FXR mediate the clinical benefits of metformin. Nat Med2018; 24: 1919–1929.
80.
MikovMAl-SalamiHGolocorbin-KonS. Potentials and limitations of bile acids and probiotics in Diabetes mellitus. In Chin-Pin Liu (editor) Type I diabetes – complications, pathogenesis and alternative treatments. InTech, Rijeka, Croatia. 2011, pp. 365–402. ISBN 978- 953-307-756-7.
